GHK-Cu / TB-500 / BPC-157 / KPV research blend
Klow
Research blend of GHK-Cu (50 mg) + TB-500 (10 mg) + BPC-157 (10 mg) + KPV (10 mg) supplied as a lyophilized single-vial preparation, 80 mg total peptide mass
Overview
Klow is the most complete of the multi-component repair blends. It combines four peptides in a single lyophilized vial: GHK-Cu (50 mg), TB-500 (10 mg), BPC-157 (10 mg) and KPV (10 mg), for 80 mg total peptide mass. Editorially, the identity of the blend is direct: Klow addresses all four mechanistic layers of tissue repair simultaneously. Where Aura covers three (gene expression, vascular supply, inflammation control) and Glow covers three (gene expression, vascular supply, cellular migration), Klow covers all four (gene expression, vascular supply, cellular migration, inflammation control). It is Aura plus TB-500 and Glow plus KPV. When all four peptides are available and the intended use warrants their combined effect, Klow is the most comprehensive repair option in the blend catalog.
The mechanistic argument for the four-way combination has a specific logic worth naming. Tissue repair is not one process — it is a coordinated cascade. Gene-level ECM signalling determines what structural proteins get built (GHK-Cu drives this through modulation of thousands of genes). Vascular supply determines whether the repair site has the metabolic support to build them (BPC-157 drives VEGF-mediated angiogenesis and fibroblast recruitment). Cellular migration determines whether the right cells arrive at the right places (TB-500 regulates the actin dynamics that let stem cells and repair cells migrate). And crucially — this is the KPV contribution — inflammatory environment control determines whether the whole cascade can proceed or is antagonised by chronic inflammation. In tissue-repair contexts where the inflammatory environment is a rate-limiting factor, adding KPV to Glow's three-component base makes the other three components meaningfully more effective. That is the mechanism argument for Klow as a distinct blend rather than a variation on Glow.
The dose profile at reference reconstitution follows the same 5 mL bacteriostatic water reference used across the multi-component repair blends. Reconstituting the 80 mg vial gives GHK-Cu 10 mg/mL, TB-500 2 mg/mL, BPC-157 2 mg/mL and KPV 2 mg/mL in solution. An 0.2 mL injection delivers GHK-Cu 2.0 mg + TB-500 0.4 mg + BPC-157 0.4 mg + KPV 0.4 mg per injection. All four components are within their individually-established therapeutic ranges for maintenance dosing at that per-injection dose. As with Glow, the TB-500 component is at maintenance rather than acute-injury loading levels; if a use case requires full TB-500 loading, supplemental TB-500 dosing during the loading phase should be considered.
The evidence position is unchanged from the other blends: combination-specific human trial evidence for the four-way Klow combination does not exist. No randomised placebo-controlled trial has evaluated GHK-Cu + TB-500 + BPC-157 + KPV as a single product. Component-level evidence for each of the four peptides is real (see the individual compound pages) but does not automatically constitute evidence for the specific four-way combination. Klow is the highest-value repair blend in the catalog when all four mechanisms are desired; it inherits the biology of its components without inheriting clinical validation that no combination trial has produced.
Quick Facts & Evidence
- Category
- GHK-Cu / TB-500 / BPC-157 / KPV research blend
- Research area
- Research blend
- Most studied for
- Comprehensive tissue repair
- Chronic-inflammation-associated repair contexts
- Combined structural and aesthetic support
- General maintenance recovery
- Clinical status
- Research use only — no approved clinical indication
- Human evidence
- Preclinical Evidence
- Regulatory status
- Not approved by FDA, EMA or MHRA
Preclinical Evidence
Data are from animal models, cell studies, or anecdotal community reports. No controlled human evidence.
Research Protocols
Research Protocol Snapshot
Preparation covered on this page
Freeze-dried injectable research format (four-component repair blend)
This page covers the RUO lyophilized Klow blend vial reconstituted with bacteriostatic water for subcutaneous research use, following the standard Healthy Mango preparation convention. Klow is Glow + KPV — adding upstream NF-κB suppression to the three-component structural repair blend. The practitioner reference calls Klow the most complete of the repair blends when all four components are available.
Klow research values at a glance.
| Item | Example value |
|---|---|
| Vial size | 80 mg total (GHK-Cu 50 mg + TB-500 10 mg + BPC-157 10 mg + KPV 10 mg) |
| Liquid used to mix | Bacteriostatic water |
| Amount of liquid added | 5.0 mL |
| Final concentration (mixed) | GHK-Cu 10 mg/mL; TB-500 2 mg/mL; BPC-157 2 mg/mL; KPV 2 mg/mL |
| How it's given | Subcutaneous injection |
| Research dose (20 units = 0.2 mL) | GHK-Cu 2.0 mg + TB-500 0.4 mg + BPC-157 0.4 mg + KPV 0.4 mg per injection |
| Injections per vial | 25 (5-week supply at 5× per week) |
| Frequency | 5× per week |
| Cycling | 3 months on / 1 month off |
Reported Dosing
The practitioner-reference research protocol for Klow is a single 20-unit (0.2 mL) subcutaneous injection five times per week, run in 3-month cycles with a 1-month washout. That shot delivers GHK-Cu 2.0 mg + TB-500 0.4 mg + BPC-157 0.4 mg + KPV 0.4 mg — the four-way parallel delivery that gives Klow its editorial identity. It is educational reference, not a recommendation.
The Reported Protocol
| Dose | Frequency | Duration | Notes |
|---|---|---|---|
| 20 units (0.2 mL): GHK-Cu 2.0 mg + TB-500 0.4 mg + BPC-157 0.4 mg + KPV 0.4 mg | 5× per week, subcutaneous | 3 months on / 1 month off | One 80 mg vial = 25 injections = 5-week supply |
Why protocols vary
The four ingredients target four complementary repair layers: GHK-Cu drives ECM gene modulation, TB-500 drives cytoskeletal cell migration, BPC-157 drives VEGF angiogenesis and fibroblast recruitment, and KPV downregulates NF-κB — creating the permissive low-inflammation environment in which the other three components are most effective. The Guide's editorial framing is that adding KPV's anti-inflammatory action to Glow creates the best possible environment for the other three.
TB-500 at 0.4 mg per injection is a maintenance-level dose, not loading level (5–10 mg TB-500 per week); acute musculoskeletal loading requires a standalone TB-500 vial in parallel.
The 3-month-on / 1-month-off cadence prevents receptor-system adaptation across long-term four-target repair signalling.
Preparing the Solution
Turning the freeze-dried blend into a measurable liquid.
Blend composition
80 mg total peptide (GHK-Cu 50 mg + TB-500 10 mg + BPC-157 10 mg + KPV 10 mg)
The vial holds four lyophilized peptides in the same cake. Reconstituting with 5.0 mL bacteriostatic water dissolves all four at once. Because the ingredients are unevenly weighted, the per-ingredient concentrations differ (GHK-Cu at 10 mg/mL, the three others at 2 mg/mL each). A single 0.2 mL injection delivers GHK-Cu 2.0 mg + TB-500 0.4 mg + BPC-157 0.4 mg + KPV 0.4 mg.
GHK-Cu
- Mass in vial
- 50 mg
- Share of total
- 62.5%
- Concentration after mixing
- 10 mg/mL
- Reported per-injection dose
- 2.0 mg per injection
TB-500
- Mass in vial
- 10 mg
- Share of total
- 12.5%
- Concentration after mixing
- 2 mg/mL
- Reported per-injection dose
- 0.4 mg per injection (maintenance level, not loading)
BPC-157
- Mass in vial
- 10 mg
- Share of total
- 12.5%
- Concentration after mixing
- 2 mg/mL
- Reported per-injection dose
- 0.4 mg per injection
KPV
- Mass in vial
- 10 mg
- Share of total
- 12.5%
- Concentration after mixing
- 2 mg/mL
- Reported per-injection dose
- 0.4 mg per injection
One reconstitution, one injection volume — all four ingredients arrive together in parallel. Klow adds KPV to Glow's three-ingredient structure; the extra NF-κB suppression is designed to create the permissive low-inflammation environment in which the other three components are most effective.
Documented in the practitioner reference (chapter 32)
Documented preparation
The documented research protocol is based on this preparation concentration.
Freeze-dried powder: 80 mg blend vial (GHK-Cu 50 mg + TB-500 10 mg + BPC-157 10 mg + KPV 10 mg)
Diluent: 5.0 mL bacteriostatic water
Final concentration: 16 mg/mL total (GHK-Cu 10 + TB 2 + BPC 2 + KPV 2 mg/mL)
Vial and volume from the practitioner reference; per-ingredient concentrations calculated · Research-practitioner guide
Your vial
Matching preparation
Bacteriostatic water
5mL
Resulting concentration
16 mg/mL
Equivalent volume
The reported research amount of 3.2 mg is contained within
0.2mL
of the prepared solution now in your vial.
Show calculation
- Documented concentration
- 80 mg ÷ 5 mL = 16 mg/mL
- Bacteriostatic water to match the documented concentration
- 80 mg ÷ 16 mg/mL = 5 mL
- Equivalent volume at this concentration
- 3.2 mg ÷ 16 mg/mL = 0.2 mL
This tool performs arithmetic conversions using the preparation example and reported research amount shown on this page. It does not recommend an amount, route, preparation method, or use.
This tool performs arithmetic conversions using the preparation example and reported research amount shown on this page. It does not recommend an amount, route, preparation method, or use.Sources for these values
- Documented in the practitioner reference (total-blend arithmetic; per-ingredient split shown above; 20-unit injection = 0.2 mL = 3.2 mg total)Research-practitioner guide
This example explains how concentration and volume are calculated for the standard RUO blend preparation. It is not a preparation guide.
How It's Given
Method used for this format
Subcutaneous injection, 5× per week
Documented in the practitioner reference · Research-practitioner guide
Why this method
All four ingredients are peptides that would be degraded by gastrointestinal proteolysis; the subcutaneous route delivers them into circulation intact.
Systemic subcutaneous dosing is used because the mechanism relies on tissue-wide signalling (ECM gene regulation, cytoskeletal migration, angiogenesis, NF-κB suppression) rather than a localised depot.
Injection sites reported
- Abdomen (rotate sites)
- Front of the thigh
- Back of the upper arm
- Avoid scarred, bruised, inflamed, or infected skin
Storage
Before mixing
- Refrigerate 2–8 °C
- Protect from light — copper is photosensitive
- Do not freeze
General RUO practice; GHK-Cu photosensitivity · Research-practitioner guide
After mixing
- Refrigerate 2–8 °C
- Use within the 5-week vial supply window
- Do not freeze
- Discard if cloudy or discoloured
General RUO practice; supply-window per practitioner reference · Research-practitioner guide
Handling
- Direct diluent slowly down the vial wall
- Gently swirl until dissolved — do not shake
- New sterile needle each draw
- Do not share vials
General RUO practice · Research-practitioner guide
Storage guidance summarises standard RUO peptide handling. TB-500 (the 17-amino-acid fragment used in this blend) is separately WADA-prohibited in athletes; blend use inherits this restriction.
Common Cycle
The practitioner reference frames Klow as 3-month active cycles followed by a 1-month washout.
- Cycle Length
- 3 months on per cycle
- Break Before the Next Cycle
- 1-month washout between cycles
- What the Research Shows
- No blend-specific long-term trial exists; individual-component pharmacology characterised in Pickart 2018 (GHK-Cu genome-wide), Seiwerth 2019 (BPC-157), Kannengiesser 2014 (KPV / IBD), and Goldstein 1972 (thymosin β4 parent-protein)
Documented in the practitioner reference; individual-component literature · Research-practitioner guide
All four ingredients are pro-angiogenic and the blend is contraindicated in active cancer; Wilson's disease and copper metabolism disorders are additional contraindications because of the GHK-Cu component.
Compound Overview
Current areas of research
Component-level effects and grey-market experience. No blend-specific trial evidence.
- Comprehensive tissue-repair support drawing on the four complementary component mechanisms
- Anti-inflammatory support from KPV in chronic-inflammation contexts (relatively rapid effect)
- Gene-level and structural repair (GHK-Cu, BPC-157, TB-500) builds over 4–12 weeks
- The most mechanism-complete repair blend in the catalog when all four peptides are needed
Mechanism of action
Klow is the most complete of the multi-component repair blends. It combines four peptides in a single lyophilized vial: GHK-Cu (50 mg), TB-500 (10 mg), BPC-157 (10 mg) and KPV (10 mg), for 80 mg total peptide mass. Editorially, the identity of the blend is direct: Klow addresses all four mechanistic layers of tissue repair simultaneously. Where Aura covers three (gene expression, vascular supply, inflammation control) and Glow covers three (gene expression, vascular supply, cellular migration), Klow covers all four (gene expression, vascular supply, cellular migration, inflammation control). It is Aura plus TB-500 and Glow plus KPV. When all four peptides are available and the intended use warrants their combined effect, Klow is the most comprehensive repair option in the blend catalog.
The mechanistic argument for the four-way combination has a specific logic worth naming. Tissue repair is not one process — it is a coordinated cascade. Gene-level ECM signalling determines what structural proteins get built (GHK-Cu drives this through modulation of thousands of genes). Vascular supply determines whether the repair site has the metabolic support to build them (BPC-157 drives VEGF-mediated angiogenesis and fibroblast recruitment). Cellular migration determines whether the right cells arrive at the right places (TB-500 regulates the actin dynamics that let stem cells and repair cells migrate). And crucially — this is the KPV contribution — inflammatory environment control determines whether the whole cascade can proceed or is antagonised by chronic inflammation. In tissue-repair contexts where the inflammatory environment is a rate-limiting factor, adding KPV to Glow's three-component base makes the other three components meaningfully more effective. That is the mechanism argument for Klow as a distinct blend rather than a variation on Glow.
The dose profile at reference reconstitution follows the same 5 mL bacteriostatic water reference used across the multi-component repair blends. Reconstituting the 80 mg vial gives GHK-Cu 10 mg/mL, TB-500 2 mg/mL, BPC-157 2 mg/mL and KPV 2 mg/mL in solution. An 0.2 mL injection delivers GHK-Cu 2.0 mg + TB-500 0.4 mg + BPC-157 0.4 mg + KPV 0.4 mg per injection. All four components are within their individually-established therapeutic ranges for maintenance dosing at that per-injection dose. As with Glow, the TB-500 component is at maintenance rather than acute-injury loading levels; if a use case requires full TB-500 loading, supplemental TB-500 dosing during the loading phase should be considered.
The evidence position is unchanged from the other blends: combination-specific human trial evidence for the four-way Klow combination does not exist. No randomised placebo-controlled trial has evaluated GHK-Cu + TB-500 + BPC-157 + KPV as a single product. Component-level evidence for each of the four peptides is real (see the individual compound pages) but does not automatically constitute evidence for the specific four-way combination. Klow is the highest-value repair blend in the catalog when all four mechanisms are desired; it inherits the biology of its components without inheriting clinical validation that no combination trial has produced.
- Four-component comprehensive repair blend: GHK-Cu 50 mg + TB-500 10 mg + BPC-157 10 mg + KPV 10 mg = 80 mg total
- The only blend that addresses all four mechanistic layers of tissue repair — gene expression, vascular supply, cellular migration, and inflammation control
- Blend-specific human trial evidence does not exist; component-level evidence is real but does not automatically validate the four-way combination
Human research
No blend-specific research literature exists for Klow. Component-level evidence is where the science lives: GHK-Cu (Pickart 2018), BPC-157 (Seiwerth 2019, Sikiric 2018), TB-500 (Goldstein thymosin discovery and follow-up), KPV (Kannengiesser 2014).
The mechanism argument for adding KPV to the three-component Glow base is the reason Klow exists as a distinct blend rather than a variation. In chronic-inflammation-associated repair contexts, KPV's NF-κB suppression makes the other three components meaningfully more effective — a mechanistic story worth understanding even in the absence of blend-specific trial validation.
Pickart 2018 GHK-Cu review
Framework for the GHK-Cu component.
Seiwerth 2019 BPC-157 review
Framework for the BPC-157 component.
Kannengiesser 2014 KPV IBD study
Representative KPV anti-inflammatory literature.
Goldstein 1972 thymosin discovery
Foundational discovery of the thymosin family (parent of TB-500).
Klow is a research blend without any combination-product regulatory authorisation. Each component has its own regulatory profile — see the individual compound pages.
No randomised placebo-controlled trial of Klow as a blend exists.
BPC-157 WADA prohibition applies.
Safety considerations
Component-level side effects apply.
- Mild injection-site reactions
- Mild bruising from copper component
- Component-level side effects apply for all four peptides
- Long-term safety of the specific four-way combination not characterised
All component-level warnings apply. Blend format does not attenuate any component warning.
- Active or recent malignancy — all components have relevant activities
- Wilson's disease / copper disorders — GHK-Cu component
- Pregnancy and breastfeeding
- Hypersensitivity to any component
- BPC-157 WADA prohibited-list considerations apply
Monitoring
- Injection-site reactions
- Pigmented lesion changes
- Systemic tolerability
Frequently asked questions
Is Klow the same as Aura or Glow?
No. Klow is a distinct four-component blend that combines what Aura and Glow each offer separately. Aura = GHK-Cu + BPC-157 + KPV (three components: gene expression, vascular supply, inflammation). Glow = GHK-Cu + BPC-157 + TB-500 (three components: gene expression, vascular supply, cellular migration). Klow = GHK-Cu + BPC-157 + TB-500 + KPV (four components: all of the above). Klow is Aura plus TB-500 and Glow plus KPV.
Why add KPV specifically?
KPV suppresses the NF-κB inflammatory pathway. In tissue-repair contexts, chronic inflammation is often a rate-limiting factor — it antagonises the repair activities of the other three components. Adding KPV creates a lower-inflammation environment in which GHK-Cu's gene modulation, BPC-157's vascular repair, and TB-500's cellular migration are all more effective. That is the mechanistic argument for Klow as a distinct blend rather than a variation on Glow.
Is Klow appropriate for acute musculoskeletal injury?
At the reference dose, the TB-500 component is at maintenance rather than acute loading levels (same limitation as Glow). For acute injuries requiring full TB-500 loading, supplemental TB-500 dosing during the loading phase should be considered. For chronic tissue repair, chronic-inflammation-associated repair contexts, and general maintenance, Klow at the reference dose is at appropriate levels across all four components.
Does Klow require more warnings than Aura or Glow?
Yes — Klow inherits all warnings from all four components. That means the Aura warnings (GHK-Cu + BPC-157 + KPV) plus the additional TB-500 immune / vascular considerations. In practice this expands the safety checklist rather than fundamentally changing it, but the four-component blend is where a consumer needs to check all four component pages before using.
Is Klow better than using individual peptides?
It depends. Klow's advantage is convenience — one reconstitution, one injection delivers all four components. Its disadvantage is dose flexibility — the ratios are fixed and TB-500 is at maintenance levels rather than acute loading levels. For consumers who want all four mechanisms simultaneously at maintenance levels, Klow is very convenient. For consumers who need TB-500 acute loading or who want to titrate individual components independently, individual peptides give more control.
References
- [1]
GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration — a consolidating review — Pickart L, Vasquez-Soltero JM, Margolina A, BioMed Research International / consolidating review (2018)
- [2]
BPC 157 and Standard Angiogenic Growth Factors — Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing — Seiwerth S, Milavic M, Vukojevic J, et al., Frontiers in Pharmacology (2019)
- [3]
The α-MSH-derived tripeptide KPV is a topically active anti-inflammatory in DSS-induced colitis — Kannengiesser K, Maaser C, Heidemann J, et al., Inflammatory Bowel Diseases (2008)
- [4]
Isolation of a biologically active fraction from bovine thymus (thymosin fraction 5) — the discovery paper for the thymosin peptide family — Goldstein AL, Guha A, Zatz MM, Hardy MA, White A, Proceedings of the National Academy of Sciences (1972)
- [5]
Peptides & Compounds — The No-Jargon Guide (v5) — Healthy Mango Editorial, Healthy Mango practitioner reference (2026)
Laboratory Reference Notice
This section summarizes procedures and study parameters reported in published scientific literature and laboratory protocols. It is provided for educational and research reference only and must not be interpreted as medical advice, clinical guidance, or instructions for personal use.
Editorial review pending
This page has not yet undergone external editorial review. Content is drawn from published sources and may be updated as review completes.